Sacubitril 97 MG / valsartan 103 MG Oral Tablet [Entresto] — RxCUI 1656356
RxNorm drug concept · Semantic branded drug
RxCUI 1656356
Semantic branded drug · SBD
● Current RxNorm concept 8 FDA products
11 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1656356
Official nameSacubitril 97 MG / valsartan 103 MG Oral Tablet [Entresto]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEntresto 97 MG / 103 MG Oral Tablet
FDA products mapped8
Package NDCs mapped11
Reported Medicaid activity (SDUD)657,545 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Valsartan and Sacubitril: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Sacubitril and valsartan works on two fronts at once. One part (sacubitril) helps your body's own protective heart hormones stick around longer, which helps your kidneys get rid of...
- What exactly is this medication supposed to do for my heart failure?
- That's a really important question. A few combinations need to be avoided or watched carefully. You should never take this with an ACE inhibitor like lisinopril or enalapril at the...
- Can I take it with my other medications? I'm also on ibuprofen sometimes for pain.
🕸️ Concept Web — How Sacubitril 97 MG / valsartan 103 MG Oral Tablet... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sacubitril 97 MG / valsartan 103 MG Oral Tablet [Entresto]
RxCUI 1656356 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Sacubitril
1656328IN -
Valsartan
69749IN -
Sacubitril / valsartan
1656339MIN
-
Sacubitril
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Entresto
1656341BN
-
Entresto
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sacubitril / valsartan Oral Tablet
1656338SCDF -
Sacubitril / valsartan Oral Product
1656336SCDG -
Sacubitril / valsartan Pill
1656337SCDG -
Sacubitril / valsartan Oral Tablet [Entresto]
1656343SBDF -
Entresto Oral Product
1656344SBDG -
Entresto Pill
1656345SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Sacubitril / valsartan Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sacubitril 97 MG / valsartan 103 MG Oral Tablet
1656354SCD -
Sacubitril 97 MG
1656352SCDC -
Valsartan 103 MG
1656353SCDC -
Sacubitril 97 MG / valsartan 103 MG [Entresto]
1656355SBDC
-
Sacubitril 97 MG / valsartan 103 MG Oral Tablet
Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sacubitril 97 MG / valsartan 103 MG Oral Tablet
SCD · 1656354 -
Sacubitril 97 MG
SCDC · 1656352 -
Valsartan 103 MG
SCDC · 1656353 -
Sacubitril / valsartan Oral Tablet
SCDF · 1656338 -
Sacubitril / valsartan Oral Product
SCDG · 1656336 -
Sacubitril / valsartan Pill
SCDG · 1656337
Brand-Name Concepts
-
Sacubitril 97 MG / valsartan 103 MG [Entresto]
SBDC · 1656355 -
Sacubitril / valsartan Oral Tablet [Entresto]
SBDF · 1656343 -
Entresto Oral Product
SBDG · 1656344 -
Entresto Pill
SBDG · 1656345 -
Entresto
BN · 1656341
📦 FDA Products & Package NDCs
8 products · 11 package NDCs
11 package NDCs map to RxCUI 1656356 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00078-0659-20 | 60 TABLET, FILM COATED in 1 BOTTLE (0078-0659-20) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2015-07-07 |
| 00078-0659-67 | 180 TABLET, FILM COATED in 1 BOTTLE (0078-0659-67) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2015-07-07 |
| 00078-0696-20 | 60 TABLET, FILM COATED in 1 BOTTLE (0078-0696-20) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2015-07-07 |
| 00078-0696-67 | 180 TABLET, FILM COATED in 1 BOTTLE (0078-0696-67) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2015-07-07 |
| 00078-0777-20 | 60 TABLET, FILM COATED in 1 BOTTLE (0078-0777-20) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2015-07-07 |
| 00078-0777-67 | 180 TABLET, FILM COATED in 1 BOTTLE (0078-0777-67) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2015-07-07 |
| 00078-1231-20 | 60 PELLET in 1 BOTTLE (0078-1231-20) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2024-04-12 |
| 00078-1238-20 | 60 PELLET in 1 BOTTLE (0078-1238-20) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2024-04-12 |
| 00078-9659-50 | 28 TABLET, FILM COATED in 1 BOTTLE (0078-9659-50) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2018-08-23 |
| 00078-9777-50 | 28 TABLET, FILM COATED in 1 BOTTLE (0078-9777-50) | ENTRESTO | Novartis Pharmaceuticals Corporation | 2018-08-23 |
| 71610-0807-37 | 3120 TABLET, FILM COATED in 1 BOTTLE (71610-807-37) | ENTRESTO | Aphena Pharma Solutions - Tennessee, LLC | 2024-03-22 |
Observed labelers:
Novartis Pharmaceuticals Corporation (10) ·
Aphena Pharma Solutions - Tennessee, LLC (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.